Biology of Interactions: Antiepidermal Growth Factor Receptor Agents

摘要: Epidermal growth factor receptor (EGFR) signaling inhibition represents a highly promising arena for the application of molecularly targeted cancer therapies. Evolving from several decades systematic research in cell biology, series EGFR inhibitors both monoclonal antibody (mAb) and tyrosine kinase inhibitor (TKI) class have been developed promoted into clinical application. Several recently gained US Food Drug Administration approval therapy United States (and many other countries), including mAbs cetuximab panitumumab, small molecule TKIs gefitinib, erlotinib, lapatinib. The rapidly expanding preclinical data contributing to these drug registrations validates central role as an important molecular target epithelial malignancies. In this review, we focus primarily on biology interactions. Through improved understanding human cancers, there is anticipation that more tumor-selective approaches with diminished collateral normal tissue toxicity can be advanced. Many questions remain answered, particularly regard how best combine conventional therapies, select those patients (tumors) most likely benefit strategies.